Name
RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: William Gradishar, MD, FASCO, FACP
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL